NAFLD VS MAFLD. The evidence-based debate has come. Time to change?

A discussion about the clinical evidence on all-cause and specific mortality of MAFLD.
PUBLISHED IN: Ann Hepatol 2022.

Commentary

In this text, D. García-Compeán and A. R. Jiménez-Rodríguez (University Hospital “Dr. José E. González” and, Universidad Autónoma de Nuevo León, Monterrey, Mexico) discuss, in general terms, the clinical evidence generated to date in cross-sectional and longitudinal studies focusing on clinical characteristics and outcomes, mainly on all-cause and specific mortality of MAFLD.

Share the article
Dr. D. Beard

Dr. D. Beard

Articles: 190

Leave a Reply

Your email address will not be published. Required fields are marked *

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES